Product Description
Oxymorphone is used to relieve pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated. Oxymorphone belongs to the group of medicines called narcotic analgesics (pain medicines). It acts in the central nervous system (CNS) to relieve pain. (Sourced from: https://www.mayoclinic.org/drugs-supplements/oxymorphone-oral-route/description/drg-20071555)
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Canada | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/25/2025 |
News Article |
Pain Management Drugs Market Size Worth USD 125.68 Billion by 2034 Driven by Aging Population and Rising Chronic Pain Cases |
|
02/28/2025 |
News Article |
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results |
|
07/12/2024 |
News Article |
Pain Management Drugs Market Size to Worth USD 120.16 Bn by 2033 |
|
03/01/2024 |
News Article |
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results |